MX385265B - Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas - Google Patents

Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas

Info

Publication number
MX385265B
MX385265B MX2019013260A MX2019013260A MX385265B MX 385265 B MX385265 B MX 385265B MX 2019013260 A MX2019013260 A MX 2019013260A MX 2019013260 A MX2019013260 A MX 2019013260A MX 385265 B MX385265 B MX 385265B
Authority
MX
Mexico
Prior art keywords
oxy
profrugs
dimethylprop
noate
octan
Prior art date
Application number
MX2019013260A
Other languages
English (en)
Other versions
MX2019013260A (es
Inventor
Eric M Gordon
John Freund
Mark A Gallop
Matthew Alexander James Duncton
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of MX2019013260A publication Critical patent/MX2019013260A/es
Publication of MX385265B publication Critical patent/MX385265B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)

Abstract

Se describen compuestos que inhiben la ß-lactamasa, métodos terapéuticos de uso de los compuestos que inhiben la ß-lactamasa, particularmente en combinación con antibiótico de ß-lactama y composicoines farmacéuticas de los mismos. Los compuestos que inhiben la ß-lactamasa son apropiados para administración oral.
MX2019013260A 2017-05-10 2018-05-02 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas MX385265B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762504523P 2017-05-10 2017-05-10
US201762551043P 2017-08-28 2017-08-28
US15/934,497 US10085999B1 (en) 2017-05-10 2018-03-23 Beta-lactamase inhibitors and uses thereof
PCT/US2018/030652 WO2018208557A1 (en) 2017-05-10 2018-05-02 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections

Publications (2)

Publication Number Publication Date
MX2019013260A MX2019013260A (es) 2021-08-11
MX385265B true MX385265B (es) 2025-03-18

Family

ID=63639355

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013260A MX385265B (es) 2017-05-10 2018-05-02 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas
MX2021008379A MX2021008379A (es) 2017-05-10 2019-11-06 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008379A MX2021008379A (es) 2017-05-10 2019-11-06 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.

Country Status (22)

Country Link
US (6) US10085999B1 (es)
EP (1) EP3625233B9 (es)
JP (2) JP6909924B2 (es)
KR (1) KR102411517B1 (es)
CN (1) CN110662746B (es)
AU (2) AU2018266566B2 (es)
CA (2) CA3062619C (es)
DK (1) DK3625233T5 (es)
ES (1) ES2955871T3 (es)
FI (1) FI3625233T5 (es)
HR (1) HRP20230977T1 (es)
HU (1) HUE062752T2 (es)
IL (2) IL296379B2 (es)
LT (1) LT3625233T (es)
MX (2) MX385265B (es)
PL (1) PL3625233T3 (es)
PT (1) PT3625233T (es)
RS (1) RS64547B9 (es)
RU (1) RU2753401C2 (es)
SG (2) SG10202102306TA (es)
SI (1) SI3625233T1 (es)
WO (1) WO2018208557A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US10280161B2 (en) * 2017-10-02 2019-05-07 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
WO2020072442A1 (en) 2018-10-01 2020-04-09 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN113614084A (zh) * 2019-03-12 2021-11-05 阿里萨制药公司 阿维巴坦衍生物的晶型
WO2020219405A1 (en) * 2019-04-26 2020-10-29 Merck Sharp & Dohme Corp. Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
CA3152300C (en) 2019-08-29 2024-04-30 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
US20210186983A1 (en) * 2019-12-20 2021-06-24 Arixa Pharmaceuticals, Inc. Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
CN117157078A (zh) * 2021-04-05 2023-12-01 Qpex生物制药有限公司 头孢布烯给药方案
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN119431373B (zh) * 2024-07-24 2025-08-08 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途
CN119841826A (zh) * 2024-09-30 2025-04-18 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3658849A (en) 1969-02-19 1972-04-25 Reynolds Tobacco Co R Treatment of 2-substituted aldehydes with lead dioxide
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3045373A1 (de) 1980-12-02 1982-07-01 Henkel KGaA, 4000 Düsseldorf Verwendung von estern der 3-hydrody-2,2-dimethylpropionsaeure als riechstoffe, diese enthaltende riechstoffkompositionen und 3-hydroxy-2,2-dimethyl-propionsaeurepropylester
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2316273A1 (en) 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained-release composition, method of its production and use thereof
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002092606A1 (en) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Fused imidazolidine derivatives, process for preparation of the same and use thereof
JP2007505136A (ja) 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
US20090069419A1 (en) 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CN101918407B (zh) * 2008-01-18 2014-02-26 默沙东公司 β-内酰胺酶抑制剂
GB0801401D0 (en) 2008-01-25 2008-03-05 Barry Callebaut Ag Composition
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
SMT201900482T1 (it) 2010-04-20 2019-09-09 Fujifilm Toyama Chemical Co Ltd Derivato dell'acido idrossammico
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
DE102010033015B4 (de) 2010-07-31 2016-03-17 Gaplast Gmbh Einmal-Applikator
SG191320A1 (en) 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
ES2565092T3 (es) 2011-05-30 2016-03-31 Sumitomo Chemical Co., Ltd. Compuestos de ciclohexanona y herbicidas que los comprenden
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2013180197A1 (ja) * 2012-05-30 2013-12-05 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規β－ラクタマーゼ阻害剤とその製造法
CN107980000A (zh) * 2014-04-18 2018-05-01 沃克哈特有限公司 包含抗菌剂的药物组合物
AU2015316400A1 (en) 2014-09-12 2017-04-06 Fujifilm Toyama Chemical Co., Ltd. Method for using novel hydroxamic acid derivative and antibacterial substance in combination
MX2017002967A (es) 2014-09-12 2017-05-30 Toyama Chemical Co Ltd Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017037607A1 (en) * 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
EP3281942A4 (en) 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
US20170165371A1 (en) 2017-02-22 2017-06-15 Joel Steven Goldberg Novel synthesis of potential ester prodrugs
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3625233B9 (en) 2023-10-25
KR20200004874A (ko) 2020-01-14
CA3153583A1 (en) 2018-11-15
IL270330A (es) 2019-12-31
AU2020227077A1 (en) 2020-09-24
FI3625233T3 (fi) 2023-09-05
JP2021165298A (ja) 2021-10-14
US10500211B2 (en) 2019-12-10
MX2021008379A (es) 2021-08-11
EP3625233A1 (en) 2020-03-25
KR102411517B1 (ko) 2022-06-21
FI3625233T5 (fi) 2023-12-12
HRP20230977T1 (hr) 2023-12-08
AU2020227077B2 (en) 2022-10-20
CA3062619A1 (en) 2018-11-15
PL3625233T3 (pl) 2023-10-23
DK3625233T5 (da) 2024-02-05
PT3625233T (pt) 2023-09-19
ES2955871T9 (es) 2023-12-19
RU2753401C2 (ru) 2021-08-16
WO2018208557A1 (en) 2018-11-15
AU2018266566A1 (en) 2019-11-07
US20190022102A1 (en) 2019-01-24
SG11201909429VA (en) 2019-11-28
ES2955871T3 (es) 2023-12-07
RU2019135891A (ru) 2021-06-10
IL270330B (en) 2022-10-01
CN110662746B (zh) 2022-08-19
IL296379B2 (en) 2024-10-01
RU2021121906A3 (es) 2022-02-17
US10722521B2 (en) 2020-07-28
LT3625233T (lt) 2023-08-25
DK3625233T3 (da) 2023-08-28
JP6909924B2 (ja) 2021-07-28
AU2018266566B2 (en) 2020-06-04
US20230201218A1 (en) 2023-06-29
IL296379B1 (en) 2024-06-01
RS64547B1 (sr) 2023-09-29
IL296379A (en) 2022-11-01
RS64547B9 (sr) 2024-02-29
CA3062619C (en) 2022-06-21
US20200046724A1 (en) 2020-02-13
JP2020519684A (ja) 2020-07-02
CN110662746A (zh) 2020-01-07
EP3625233B1 (en) 2023-07-12
BR112019023598A2 (pt) 2020-05-26
SG10202102306TA (en) 2021-04-29
IL270330B2 (en) 2023-02-01
US20200297733A1 (en) 2020-09-24
NZ758353A (en) 2021-10-29
RU2021121906A (ru) 2021-08-02
RU2019135891A3 (es) 2021-06-10
US20240415847A1 (en) 2024-12-19
MX2019013260A (es) 2021-08-11
HUE062752T2 (hu) 2023-12-28
US10085999B1 (en) 2018-10-02
SI3625233T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
MX385265B (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
ECSP19051352A (es) Inhibidores selectivos de jak1
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201991403A1 (ru) Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
EA201992679A1 (ru) N-замещенные индольные производные
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
BR112021011325A2 (pt) Derivados de rapamicina
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
BR112018074913A2 (pt) formulação farmacêutica de cineol e amoxicilina
UA113233U (uk) Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента